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Abstract
Introduction
Chronic proton-pump inhibitor (PPI) prescription is on the rise in the last decade with an increased
prevalence in the elderly population. For most patients, this class of drugs is the primary treatment for
various diseases. Even though PPIs are generally safe, long-term use has been associated with multiple
adverse effects like bone fractures. The extent of the association between PPI and fracture is still unclear in
women aged between 50 and 65 years. Besides, many other variables and risk factors must be accounted for
in the analysis of this relation.

Methods
This is a retrospective case-control study looking at women 50-65 years of age who presented to Genesys
Health for a low-impact fall. Data were extracted from electronic medical records and fracture outcomes; PPI
therapy exposure and duration were determined. Chi-square analysis was performed to determine the
association between chronic PPI therapy and fracture outcome and independently analyzed for major risk
factors of osteoporosis, including smoking, low body mass index, and cancer.

Results
Patients in the chronic PPI therapy group were found to have a decreased fracture outcome overall in each
subcategory of risk factors. When adjusting for all risk factors, there was a significant but weak association
between chronic PPI therapy and increased fracture outcome.

Conclusion
With different results from previous studies, this study sheds new light on this debate. More studies need to
be carried out to determine the association between chronic PPI therapy and fracture outcomes in
postmenopausal women.

Categories: Family/General Practice, Orthopedics, Public Health
Keywords: osteoporosis, chronic smoking, body mass index (bmi), fall injury, simple fall, senile osteoporosis, protonpump inhibitor, pathological femoral shaft fracture, prevention of osteoporosis, osteoporosis management

Introduction
Chronic proton-pump inhibitor (PPI) prescription is on the rise in the last decade with an increased
prevalence in the elderly population [1-3]. For most patients, this class of drugs is the primary treatment for
various diseases, including peptic ulcer disease, esophagitis, prevention of nonsteroidal anti-inflammatory
drugs associated with ulcers, gastroesophageal reflux disease, Zollinger-Ellison syndrome, and functional
dyspepsia [4]. Even though PPIs are generally safe, long-term use has been associated with multiple adverse
effects like bone fractures, hypomagnesemia, microscopic colitis, kidney disease, community-acquired
pneumonia, and increased risk of Clostridium difficile infection [5]. Furthermore, PPIs are overused in
outpatient and inpatient settings, especially in intensive care units [6]. As a result, this worldwide and often
open-ended use of PPIs can have negative and unintended consequences in the long run.
Several studies have evaluated the association between PPI usage and fracture risk [7-14]. Furthermore, PPI
use has been associated with osteoporosis [15-17]. This led to speculations about the increased fracture risk
in postmenopausal women and has been observed in multiple studies [18-19]. Nonetheless, some studies
showed that PPI use in postmenopausal women was not associated with an increased risk of hip fracture but
modestly associated with other fractures [20]. Also, some studies have shown that PPI use was not related to
fractures in patients aged 50-79 without risk factors [21].
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To date, no prospective, randomized, blinded controlled trials have been done to analyze the association
between chronic PPI therapy and fracture risk. The extent of the association between PPI and fracture is still
unclear in women aged between 50 and 65 years. Besides, many variables and risk factors must be accounted
for in the analysis of this relation. Our study was conducted to determine if there is a clinically significant
increased outcome in the osteoporotic fracture in women 50-65 years on chronic PPI therapy.

Materials And Methods
This was a retrospective, case-control study that included women aged between 50 and 65 years presenting
to Genesys Health for a low-impact fall. We received approval from the institutional review board, and the
approval number was 11564273; the board's name is Genesys Health. A low-impact fall was defined as a fall
from no greater than standing height due to slipping, tripping, or stumbling on the same level. This was
determined by the International Classification of Diseases (ICD)-9 and ICD-10 codes. High-impact falls,
defined as falls resulting from a sporting injury or falling from a height greater than standing, were excluded.
If ICD-9/ICD-10 codes did not capture the type of impact, it was determined by the patient's chart review
(history section or emergency department provider's note). Patients who were selected must have had more
than one prior admission/visit for any reason to determine exposure and duration of PPI use. Those with
only one admission/visit were excluded from the study.
Fracture outcome was determined by reviewing each patient's chart at the fall visit/admission, and the acute
fracture was determined from the imaging section. Any mention of an old fracture was excluded. Chronicity
of PPI therapy, defined as more than one year of use, was determined by prescription entry dates from the
patient's outpatient medication list. Any PPI script that was ordered in the inpatient setting was excluded.
Risk factors for osteoporosis (smoking, low body mass index (BMI) <18 kg/m2, Crohn's disease, ulcerative
colitis, hyperparathyroidism, chronic kidney disease, cancer, and rheumatoid arthritis) were flagged. Risk
factors that could alter fracture risks, such as medications including bisphosphonates and thiazide, were also
flagged. Each risk factor was independently analyzed for fracture outcome with chronic PPI therapy
compared to no PPI therapy. Categorical variables were summarized with frequencies and proportions and
were compared using the Chi-square test or Fisher's exact test. A p-value <0.05 was considered statistically
significant.

Results
A total of 1,483 patients met the inclusion criteria. One hundred twenty-one patients were excluded due to
having high-impact falls. Of the remaining 1,362, 864 patients had no exposure to PPI therapy, and 498
patients had PPI exposure. Only 202 patients had exposure to PPIs for greater than one year. In total, 864
patients (81.1%) were identified not to have been exposed to PPI, while only 202 patients (18.9%) were
determined to have been on PPIs greater than one year (Figure 1).
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FIGURE 1: Total number of patients recruited.
PPI: proton-pump inhibitor.

Overall fracture risk was decreased by about 10% in patients on long-term PPI therapy (28.2%) as opposed to
patients with no PPI use (39.7%), and this was clinically significant (X2 = 9.2, p = 0.002); odds ratio is 0.6
(95% confidence interval: 0.43 to 0.83) (p-value = 0.002). Yet, these data were not adjusted for major risk
factors of osteoporosis. Each category of major risk factors was independently analyzed. The data were not
included for those risk factors with a very small sample size due to invalid clinical significance. Regarding
the risk category of low BMI (<18 kg/m2), only 22 patients (3%) were identified to have been on long-term
PPI therapy. The fracture risk was reduced in patients with regular BMI on long-term PPI therapy. Still, the
decrease was more pronounced in patients with a low BMI (X2 = 8.444, p = 0.004) (Figure 2).
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FIGURE 2: Fracture outcomes in patients with regular and low BMI.
Blue column indicates no PPI, and yellow column indicates PPI for more than one year. BMI: body mass index;
PPI: proton-pump inhibitor.

Concerning the cancer risk category, only 55 patients (6%) were identified to have been on long-term PPI
therapy. The fracture risk was low in those patients on long-term PPI therapy without cancer. Still, the
decrease was more pronounced in cancer patients (X 2 = 8. 973, p = 0.003) (Figure 3).

FIGURE 3: Fractures outcome in patients with cancer.
Blue column indicates no PPI, and yellow column indicates PPI for more than one year. PPI: proton-pump
inhibitor.

Concerning smoking, about 123 patients (12%) were identified to have been on long-term PPI therapy. The
fracture risk was low in nonsmoker patients on long-term PPI therapy. Yet, the decreased fracture risk was
more pronounced in smokers (X2 = 4.741, p = 0.029) (Figure 4).
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FIGURE 4: Fractures outcome in smokers.
Blue column indicates no PPI, and yellow column indicates PPI for more than one year. PPI: proton-pump
inhibitor.

All three separate analyses were clinically significant. Nonetheless, adjusting for the variables, such as
cancer, ulcerative colitis, low BMI, smoking, and thiazides, there was a significant but weak association
between the PPI more than one-year group and fracture outcome (R² = 0.003, p = 0.002).

Discussion
Osteoporosis is a multifactorial skeletal disease characterized by reduced bone strength and increased
susceptibility to bone fractures [22-23]. Postmenopausal women are far more likely to be affected by
osteoporosis and associated fractures than men [24]. According to an estimate by the National Osteoporosis
Foundation (NOF), it is estimated that there are 9.1 million women who have osteoporosis. Because of
osteoporosis, a 60-year-old woman has almost double the lifetime risk of fracture than a man of the same
age [25]. The spine, hip, distal forearm, and proximal humerus are some of the common sites for
osteoporotic fractures. Thus, osteoporotic fractures significantly affect the quality of life and cause
significant morbidity among postmenopausal women [26-27]. Vertebral fractures are the most common and
are associated with functional limitation due to acute back pain. While most cases resolve, some may
progress to chronic back pain and disability [28-29]. Hip fractures are also associated with acute pain and loss
of functionality. The recovery rate is slow, and most patients require hospitalization. While distal radial
fractures have positive recovery outcomes, they also lead to acute pain and loss of function in most cases
[26-27]. Chronic PPI use has been associated with osteoporosis [15-17]. Mechanisms suggested include
hypergastrinemia, hypochlorhydria, and possible direct bone effects [18]. Hence, it is speculated that chronic
PPI by increasing osteoporosis risk might increase fracture risk in postmenopausal women. As discussed
earlier, this might lead to chronic pain, disability, and loss of function.
Our study results show a significantly reduced fracture risk among those on PPI for more than one year
compared to those not on PPI. In addition, the risk of fracture decreased in patients on chronic PPI even
when stratified by major risk factors. This conclusion was not consistent with the conclusions seen in most
studies done on postmenopausal women [19]. A possible explanation behind the inconsistency with previous
results might include sample distribution in each group: As mentioned in the results, only about 18.9% were
identified to have been on chronic PPI as opposed to about 81.1% not on PPI therapy. Furthermore, with the
evaluation of each risk category, the reduced sample size of those patients on chronic PPI therapy was more
significant. Access to data from multiple hospitals or a larger population might have increased the sample
size and the study's power. Another reason that may have contributed to our results compared to studies
done in the past is that our patient population was only in the inpatient or the emergency room setting. This
suggests our patients probably have more comorbidity than patients presenting for a low-impact fall in an
outpatient setting such as the clinic or urgent care. Also, the difference in comorbid conditions between
groups was not determined. One group may have had a higher number of patients with the comorbid disease,
increasing the number of falls or risk factors for osteoporosis, resulting in a higher chance of fracture
outcome.
Moreover, patients included were from one hospital and likely residing in the Grand Blanc region. This could
affect fracture risk due to the prevalence of certain diseases or lack of sun exposure that could affect vitamin
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D levels and alter bone density. Besides, our data did not analyze the percentage of fracture outcomes within
each racial category. In addition, biases are a common limitation in this study by design. The patient's home
medication list was self-reported, which might be subject to recall bias. Also, patients may have used an
over-the-counter PPI intermittently, so this information may have been underreported. Likewise, patients'
compliance with PPIs may be variable, which was not further assessed. Hence, cross-referencing the
outpatient medication list to an external outpatient data set would have contributed to minimizing recall
bias. Another limitation of this study was not categorizing the major osteoporotic sites known to affect a
patient's overall functionality, as discussed earlier. Determining fracture outcomes at major osteoporotic
sites such as the hip, spine, and distal forearm would have been beneficial. Also, reporting different
doses/strengths of PPIs would have been beneficial in this study as it would have determined if PPI use has a
dose-dependent effect on fracture outcome.
However, when adjusting for some of the major risk factors for osteoporosis, such as cancer, ulcerative
colitis, low BMI, smoking, and medications, such as thiazides, that could alter fracture outcome, there is a
significant but weak association between the PPI more than one-year group and fracture outcome. This
finding was consistent with the conclusions seen in most previous studies. Practice guidelines suggest
lowering the PPI dose to the lowest effective dose to treat symptoms or disease or switching to less potent
medications such as H2 blockers to minimize the risk of adverse effects and complications. Providers should
continue practicing this recommendation. With opposing results, this study sheds new light on this debate.
More studies need to be done to determine the association between chronic PPI therapy and fracture
outcomes in postmenopausal women.

Conclusions
Our study showed that the chronic use of PPI over one year is associated with a low fracture
probability. With different results from previous studies, this study sheds new light on this debate, and more
studies need to be done to determine the association between chronic PPI therapy and fracture outcomes in
postmenopausal women, especially in regions with various influencing factors including sun exposure, racial
differences, or access to health care.
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